Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report

Saraceno, Lorenzo; Ricigliano, Vito A. G.; Cavalli, Michele; Meola, G.

doi:10.1007/s10072-017-2851-7

Cited by 9 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many drugs can cause PRES ( Abughanimeh et al, 2018 ; Vilas-Boas and Corte-Real, 2019 ; Kaur et al, 2020 ). With new antitumor agents widely used in the clinic in recent years, accumulating case reports have reported the occurrence of PRES in patients receiving targeted therapies, particularly antiangiogenic agents, such as bevacizumab ( Hamid et al, 2018 ; Katada et al, 2018 ), sunitinib ( Saraceno et al, 2017 ; Rifino et al, 2020 ), sorafenib ( Dogan et al, 2010 ; Laruelle et al, 2018 ), pazopanib ( Deguchi et al, 2018 ; Tatsumichi et al, 2021 ) and regorafenib ( Aanes et al, 2018 ).…”

Section: Discussionmentioning

confidence: 99%

“…Parieto-occipital white matter and cortex were involved, with varying degrees of temporal lobe involvement 33 (Allen et al, 2006;Ozcan et al, 2006;Martin et al, 2007;Burki et al, 2008;Koopman et al, 2008;Peter et al, 2008;Dos Reis Simões da Silva et al, 2011;Lau and Paunipagar, 2011;Lou et al, 2011;Padhy et al, 2011;Chang et al, 2012;Chelis et al, 2012;Khan et al, 2012;Lazarus et al, 2012;Sclafani et al, 2012;Seet and Rabinstein, 2012;Abbas et al, 2013;Asaithambi et al, 2013;Goto and Mimura, 2014;Levy et al, 2014;Sawaya et al, 2014;Eryılmaz et al, 2016;Miller et al, 2016;Nakamura et al, 2017;Saraceno et al, 2017;Aanes et al, 2018;Deguchi et al, 2018;Katada et al, 2018;Li et al, 2018;Rifino et al, 2020;Van Pelt et al, 2020) Vasogenic edema in the watershed areas of the frontal, parietal, and occipital lobes 7 ( Ozcan et al, 2006;Cumurciuc et al, 2008;Koopman et al, 2008;Dersch et al, 2013;Miaris et al, 2017;Katada et al, 2018;Lv et al, 2019) Basal ganglia, frontal lobe,brainstem, cerebellar hemisphere and unilateral lesion 14 (Koopman et al, 2008;…”

Section: Mri Imaging Findingsmentioning

confidence: 99%

“…In addition, there were a few rare AEs reported such as insomnia, sensory neurotoxicity, and seizure ( Huang et al, 2021 ; Liu et al, 2021 ; Lu et al, 2022 ; Nie et al, 2022 ; Shao et al, 2022 ; Zou et al, 2022 ). Although a few cases of posterior reversible encephalopathy syndrome (PRES) caused by some anti-angiogenic drugs were reported in the literature ( Koopman et al, 2008 ; Chelis et al, 2012 ; Myint et al, 2014 ; Sharma et al, 2016 ; Saraceno et al, 2017 ; Miaris et al, 2019 ; Van Pelt et al, 2020 ), no PRES has been previously reported in SCLC patients treated with anlotinib.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Zou

Zhou²,

Lv³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Anlotinib is an oral multi-targeted tyrosine kinase inhibitor as a third-line and subsequent treatment for patients with small cell lung cancer (SCLC) in China. The neurotoxicity is less reported. Posterior reversible encephalopathy syndrome (PRES) is characterized by headaches, seizures, encephalopathy, and visual disturbances, as well as focal reversible vasogenic edema seen on neuroimages. Here, we presented a case of PRES in a small cell lung cancer (SCLC) patient associated with anlotinib. A 37-year-old female patient, who had a history of diabetes, with extensive-stage SCLC received anlotinib after third-line chemotherapy. Ten cycles of anlotinib later, the patient experienced visual disturbance and was diagnosed with PRES based on the typical demyelination of white matter obtained in the brain magnetic resonance. During anlotinib therapy, the patient did not develop anti-VEGF therapy-induced hypertension. Subsequently, the patient stopped anlotinib, but she did not recover from symptoms. We also summarized the characteristics of fifty-four cases of PRES caused by antiangiogenic drugs in the literature. Based on our experience and the literature review, the incidence of PRES induced by antiangiogenic drugs is low, and the symptom can resolve upon stopping the medications. However, some cases still have a poor prognosis and the underlying mechanism requires further investigation. In addition, early detection and treatment of PRES are essential for physicians.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Mri Imaging Findingsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Zou

Zhou²,

Lv³

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The condition is more commonly noted in the context of the following conditions: malignant hypertension, eclampsia, serious kidney diseases, immunosuppressive therapy after organ transplantation, systemic lupus erythematosus, and malignant tumor treatment. Reports regarding RPLS are not uncommon during cancer therapy 4 including some chemotherapy drugs, such as paclitaxel, 5 platinum, 6 , 7 fluorouracil and irinotecan, 6 , 7 pemetrexed and gemcitabine., 8 , 9 In particular, reports have been published regarding RPLS induced by antiangiogenic drugs, such as bevacizumab, 10 – 12 sorafenib, 13 sunitinib, 14 pazopanib, 15 axitinib, 16 and cediranib. 17 This case is the first report of RPLS induced by apatinib.…”

Section: Discussionmentioning

confidence: 99%

Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review

Chai

Wang

et al. 2018

OTT

View full text Add to dashboard Cite

Reversible posterior leukoencephalopathy syndrome (RPLS) is a rare clinical-radiologic syndrome. There are reports that RPLS may be associated with cancer therapy including some chemotherapy drugs and antiangiogenic drugs. This paper reported a case of RPLS induced by apatinib, a vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase inhibitor. A 47-year-old cervical cancer patient was administered apatinib, and 3 months later, headache, dizziness, blurred vision, and hypertension appeared. She was diagnosed with RPLS by nuclear magnetic resonance imaging (MRI). After apatinib discontinuation and normotensive treatment, her symptoms completely reversed. Antiangiogenic drugs potentially damage the balance of the blood–brain barrier by directly injuring vascular endothelial cells, resulting in the occurrence of RPLS. This case is the first report of RPLS induced by apatinib.

show abstract

“…In addition, there are a few rare adverse effects reported ( 6 – 10 ). Though there have been cases of PRES induced by other VEGF inhibitors, anlotinib has not been previously reported to be associated with PRES ( 11 – 13 ). Here, we present the case of a 56-year-old female patient with lung adenocarcinoma and bone metastasis who developed PRES after being treated with anlotinib.…”

Section: Introductionmentioning

confidence: 98%

Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review

Nan

Yin

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a relatively rare clinical disease, characterized by reversible subcortical vasogenic edema. Here, we present the first reported case of PRES induced by anlotinib, a multi-target tyrosine kinase inhibitor. A 56-year-old female patient with lung adenocarcinoma and bone metastasis experienced hypertension and mental confusion when she received anti-angiogenesis treatment. PRES was diagnosed after magnetic resonance of the patient's brain revealed hyperintensities bilaterally around the cerebellum, pons, fronto-parieto-occipital areas, and corona radiate. Diffusion-weighted imaging showed hyperintensities bilaterally in the parieto-occipital cortical regions. Subsequently, the patient was diagnosed with PRES, and remission was achieved with anti-hypertensive drugs. Six cases of rare adverse effects induced by anlotinib were reviewed in the literature. Since anlotinib has been widely applied as a novel third-line treatment in patients with non-small-cell lung cancer, the association between PRES and anlotinib would benefit neurologists and oncologists in future diagnoses and treatment.

show abstract

Posterior reversible encephalopathy syndrome after long-term treatment with low-dose sunitinib: a case report

Cited by 9 publications

References 5 publications

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: A case report and literature review

Reversible posterior leukoencephalopathy syndrome induced by apatinib: a case report and literature review

Posterior Reversible Encephalopathy Syndrome Associated With Anlotinib: A Case Report and Literature Review

Contact Info

Product

Resources

About